Literature DB >> 22159832

Treatment of osteoporosis in postmenopausal hip fracture patients after geriatric rehabilitation: changes over the last decade.

M Gosch1, T Roth, C Kammerlander, B Joosten-Gstrein, U Benvenuti-Falger, M Blauth, M Lechleitner.   

Abstract

BACKGROUND: Osteoporotic hip fractures are a major cause of morbidity and mortality in postmenopausal women, and their impacts on society are substantial. Although adequate osteoporotic treatment reduces the risk of subsequent fractures and also mortality, only a minor proportion of the patients receives sufficient therapy.
OBJECTIVES: The goal of the present study was to evaluate osteoporosis treatment in two different cohorts and to describe the changes after the implementation of a Geriatric Facture Center (GFC) in cooperation with a level 1 trauma center. STUDY
DESIGN: A retrospective, single-center cross sectional study design was used.
METHODS: A total of 455 patients (70 years and older) were included at our department of geriatric medicine. The patients were split into two groups. The usual care (UC) group consisted of 327 patients admitted to our department from 2001-2004. The GFC group included 128 patients admitted from 2009-2010. In addition to recording osteoporosis therapy, we collected demographic data, comorbidities, and different functional parameters of the patients. The data were collected retrospectively using medical records. SPSS 18.0 was used for statistical analysis.
RESULTS: Of the patients, 43% in the GFC group received a specific antiresorptive or anabolic treatment (SAAT). Basic treatment with calcium and vitamin D3 was prescribed in 88% of the patients. The diagnosis "osteoporosis" was found in 73.4% of the discharge letters. In the UC group, the percentage of patients with a SAAT was 14.7%, calcium and vitamin D3 was prescribed in 30%, and the diagnosis was documented in 24.5%. All these differences are statistically significant (p < 0.0001). In the GFC group, better functional status and cognition were significantly associated with a higher rate of a prescribed SAAT, whereas age and comorbidities showed a negative association.
CONCLUSION: Our results show that the management of osteoporosis in postmenopausal hip fracture patients has significantly improved over the last decade. From our point of view, the main impact on this development is due to the implementation of a GFC with corresponding guidelines and treatment steps. In addition to structural changes, the improved evidence for osteoporosis treatment, especially of geriatric patients, has a positive influence on osteoporosis therapy.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22159832     DOI: 10.1007/s00391-011-0254-6

Source DB:  PubMed          Journal:  Z Gerontol Geriatr        ISSN: 0948-6704            Impact factor:   1.281


  27 in total

Review 1.  Hip fracture.

Authors:  Martyn Parker; Antony Johansen
Journal:  BMJ       Date:  2006-07-01

2.  Epidemiology, treatment and costs of osteoporosis in Germany--the BoneEVA Study.

Authors:  B Häussler; H Gothe; D Göl; G Glaeske; L Pientka; D Felsenberg
Journal:  Osteoporos Int       Date:  2006-09-19       Impact factor: 4.507

3.  Missed opportunities for osteoporosis treatment in patients hospitalized for hip fracture.

Authors:  Lee A Jennings; Andrew D Auerbach; Judith Maselli; Penelope S Pekow; Peter K Lindenauer; Sei J Lee
Journal:  J Am Geriatr Soc       Date:  2010-04       Impact factor: 5.562

Review 4.  Hip fracture.

Authors:  J D Zuckerman
Journal:  N Engl J Med       Date:  1996-06-06       Impact factor: 91.245

5.  Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.

Authors:  Dennis M Black; Pierre D Delmas; Richard Eastell; Ian R Reid; Steven Boonen; Jane A Cauley; Felicia Cosman; Péter Lakatos; Ping Chung Leung; Zulema Man; Carlos Mautalen; Peter Mesenbrink; Huilin Hu; John Caminis; Karen Tong; Theresa Rosario-Jansen; Joel Krasnow; Trisha F Hue; Deborah Sellmeyer; Erik Fink Eriksen; Steven R Cummings
Journal:  N Engl J Med       Date:  2007-05-03       Impact factor: 91.245

Review 6.  Efficacy and safety of pharmacological agents in managing osteoporosis in the old old: review of the evidence.

Authors:  Charles A Inderjeeth; Adrian C H Foo; Michelle M Y Lai; Paul Glendenning
Journal:  Bone       Date:  2008-12-16       Impact factor: 4.398

7.  Efficacy and safety of a once-yearly intravenous zoledronic acid 5 mg for fracture prevention in elderly postmenopausal women with osteoporosis aged 75 and older.

Authors:  Steven Boonen; Dennis M Black; Cathleen S Colón-Emeric; Richard Eastell; Jay S Magaziner; Erik Fink Eriksen; Peter Mesenbrink; Patrick Haentjens; Kenneth W Lyles
Journal:  J Am Geriatr Soc       Date:  2010-01-08       Impact factor: 5.562

8.  Effectiveness of antiresorptive agents in the prevention of recurrent hip fractures.

Authors:  S Morin; E Rahme; H Behlouli; A Tenenhouse; D Goltzman; L Pilote
Journal:  Osteoporos Int       Date:  2007-07-19       Impact factor: 4.507

9.  Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis.

Authors:  Catherine MacLean; Sydne Newberry; Margaret Maglione; Maureen McMahon; Veena Ranganath; Marika Suttorp; Walter Mojica; Martha Timmer; Alicia Alexander; Melissa McNamara; Sheetal B Desai; Annie Zhou; Susan Chen; Jason Carter; Carlo Tringale; Di Valentine; Breanne Johnsen; Jennifer Grossman
Journal:  Ann Intern Med       Date:  2007-12-17       Impact factor: 25.391

10.  Prevalence of osteoporosis in Australian women: Geelong Osteoporosis Study.

Authors:  M J Henry; J A Pasco; G C Nicholson; E Seeman; M A Kotowicz
Journal:  J Clin Densitom       Date:  2000       Impact factor: 2.963

View more
  11 in total

Review 1.  Osteoporosis and polypharmacy.

Authors:  M Gosch; M Jeske; C Kammerlander; T Roth
Journal:  Z Gerontol Geriatr       Date:  2012-08       Impact factor: 1.281

2.  [Prevalence and management of osteoporosis in trauma surgery. Implementation of national guidelines during inpatient fracture treatment].

Authors:  F Haasters; W C Prall; M Himmler; H Polzer; M Schieker; W Mutschler
Journal:  Unfallchirurg       Date:  2015-02       Impact factor: 1.000

3.  The reliability and validity of the simplified Chinese version of Male QUALEFFO-26.

Authors:  Leilei Xu; Weixiang Sun; Xiaodong Qin; Xiufen Zhu; Yong Qiu; Zezhang Zhu
Journal:  Rheumatol Int       Date:  2015-12-22       Impact factor: 2.631

4.  [Osteoporotic treatment options in geriatric patients].

Authors:  M Gosch; C Kammerlander; K Pils; M Lechleitner; U Benvenuti-Falger; T Roth; B Joosten-Gstrein; P Pietschmann
Journal:  Z Gerontol Geriatr       Date:  2012-07       Impact factor: 1.281

Review 5.  [Proximal femoral fractures in the elderly].

Authors:  Carl Neuerburg; M Gosch; W Böcker; M Blauth; C Kammerlander
Journal:  Z Gerontol Geriatr       Date:  2015-10       Impact factor: 1.281

6.  Value of a coordinated management of osteoporosis via Fracture Liaison Service for the treatment of orthogeriatric patients.

Authors:  D Schray; C Neuerburg; J Stein; M Gosch; M Schieker; W Böcker; C Kammerlander
Journal:  Eur J Trauma Emerg Surg       Date:  2016-07-25       Impact factor: 3.693

7.  Ankle fractures have features of an osteoporotic fracture.

Authors:  K M Lee; C Y Chung; S S Kwon; S H Won; S Y Lee; M K Chung; M S Park
Journal:  Osteoporos Int       Date:  2013-05-17       Impact factor: 4.507

Review 8.  [Augmentation techniques on the proximal femur].

Authors:  C Neuerburg; M Gosch; M Blauth; W Böcker; C Kammerlander
Journal:  Unfallchirurg       Date:  2015-09       Impact factor: 1.000

Review 9.  [Characteristics of pharmacotherapy in older patients with rheumatism].

Authors:  H-J Lakomek; Christian Schulz
Journal:  Z Rheumatol       Date:  2018-06       Impact factor: 1.372

Review 10.  [Osteoporosis: therapy in interface management].

Authors:  Peter Mikosch; Markus Gosch
Journal:  Wien Med Wochenschr       Date:  2013-10-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.